Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (an Australian biotechnology company) covers the month of May 2004. The registrant is a foreign private issuer reporting pursuant to Rule 13a-16. The filing serves as a compilation of six "New Issue Announcements" (Appendix 3B) submitted to the Australian Securities Exchange (ASX) between October 2003 and April 2004, detailing the issuance of ordinary shares and options.
Key Financial Metrics and Capital Structure
The filing does not provide revenue, profit, cash flow, or debt metrics. It focuses exclusively on equity capitalization and securities issuance.
- Ordinary Shares Issued: A total of 873,456 ordinary shares were issued across the reported periods.
- Options Outstanding: As of the latest report (April 2004), the company had approximately 21.56 million options outstanding across various classes (PBTAK, PBTAM, PBTAO, PBTAI, PBTAQ, PBTAS).
- Quoted Shares: 74,659,380 ordinary shares were quoted on the ASX as of April 16, 2004.
- Exercise Prices: Options were issued with exercise prices ranging from $0.50 to $1.50 AUD.
Material Changes and Issuance Details
The filing details six distinct issuance events. The most recent activity occurred in April 2004, followed by issuances in February, January, December, November, and October 2003.
| Date | Security Type | Quantity | Price/Consideration | Purpose |
|---|---|---|---|---|
| April 16, 2004 | Ordinary Shares | 400,000 | $0.70 and $0.50 | Exercise of options (PBTAS and PBTAK) |
| February 20, 2004 | Ordinary Shares | 155,502 | $0.55 | In lieu of US $65,000 corporate advisory fees |
| January 12, 2004 | Ordinary Shares | 317,954 (249,999 + 67,955) | $0.48 and $0.64 | AGM resolution and US $30,000 advisory fees |
| December 5, 2003 | Unquoted Options | 20,000 | Nil | Employee/Consultant options |
| November 27, 2003 | Unquoted Options | 500,000 | Nil | Employee/Consultant options |
| October 23, 2003 | Unquoted Options | 500,000 | Nil | In lieu of fees for share placement |
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It is a regulatory disclosure of past capital events.
Risks and Contingencies: The filing includes standard warranties to the ASX that the securities comply with the law, are not for illegal purposes, and that no rights of return exist under the Corporations Act. The company indemnifies the ASX against claims arising from breaches of these warranties.
Investor Verification Checklist
- Verify the total number of outstanding options (approx. 21.56 million) relative to the quoted share count (approx. 74.66 million) to assess potential dilution.
- Confirm the exercise prices of the outstanding options ($0.50, $0.70, $1.50) against current market prices to determine if they are in-the-money.
- Review the purpose of the February and January 2004 issuances to understand the cost of corporate advisory services paid in equity.
- Check the expiration dates of the various option classes, with the earliest expiring on December 1, 2004, and the latest on June 30, 2005.